Ryan Elliott
@ryanelliott.bsky.social
Hematology Resident Physician | Former High School Teacher | Piano Enthusiast | Proud Newfoundlander | Millennial https://buymeacoffee.com/ryanelliott
Jorge Castillo, MD, shares data on an all-oral, non-chemo, fixed-duration regimen for Waldenström macroglobulinemia using pirtobrutinib and venetoclax. The combination delivered rapid, profound and 100% overall responses with manageable side effects and high rate of deep responses. #ASH25
Wow!! 🔥🔥 CDK4/6 inhibition prevents selection of #ClonalHematopoiesis with DNA-damage repair mutations after chemotherapy! Awesome presentation from Irenaeus Chan from @kellybolton.bsky.social lab! #ASH25
📚 This T-cell NHL diagnostic slide has been circulating and provides a nice framework #medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded
Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL #CLL #Hematology www.onclive.com/view/final-c...
Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL | OncLive
Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.
onclive.com
🩸 ISTH DIC score (overt ≥ 5) Plt <50=2; 50–100=1 PT >6s=2; 3–6s=1 Fibrinogen <1.0g/L=1 D-dimer: >3× ULN=3; 1–3× ULN=2; none=0 #hemesky #medsky #coag #benignheme
Join us on October 25 for a packed day of thrombosis education for healthcare professionals. Register today at thrombosiscanada.ca/2025Conference
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology www.onclive.com/view/mosunet...
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL
Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.
onclive.com
Not hard to tell that I’m currently on thrombosis! Having a good experience with the team here at McMaster. #thrombosis #hemesky #hematology
"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation." Publié en juillet dans J Thromb Haemost. #MedSky #DIC www.sciencedirect.com/science/arti...
Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation
Compelling evidence supports the need to update the 2001 definition and diagnosis of disseminated intravascular coagulation (DIC) to reflect our curre…
sciencedirect.com
🩸📖 NEJM 2003: CLOT trial - 676 patients w/ cancer-associated thrombosis (CAT) - Dalteparin vs warfarin. Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months). Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin. #hemesky #thrombosis #medsky
🩸Cancer-associated Thrombosis Trials: LMWH more effective than VKAs CANTHANOX 2002: Enoxaparin vs VKA CLOT 2003: Dalteparin vs VKA ONCENOX 2006: Enoxaparin vs VKA LITE 2006: Tinzaparin vs VKA CATCH 2015: Tinzaparin vs VKA #thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc
CARAVAGGIO 2020 (1,170 pts): Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis
Lesson from this past week: Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis
Ven is effective (91% ORR) and well tolerated in octogenarians, but 43% hd treatment holds and 32% prolonged ramp-up. buff.ly/lNgBN1r #hemesky
Chronic myeloid leukemia is a myeloproliferative neoplasm. This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia. https://ja.ma/4mlR6ez
Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma buff.ly/bbBzTQG #hemesky #lymphoidneoplasia
🔬🩸Hemoglobin development (some fundamentals!) Embryo Hb Gower I = ζ2ε2 Hb Gower II = α2ε2 Hb Portland = ζ2γ2 Fetus HbF = α2γ2 Adult HbA = α2β2 ~97% HbA2 = α2δ2 ~2–3% HbF <1% #hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics
JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management #MPNsm #hematology #oncology www.onclive.com/view/jak-inh...
JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.
onclive.com
💊 Abatacept Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells. Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation. #medsky #IMsky #rheumsky #biologics (Herrero-Beaumont et al., 2012)
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma #mmsm #Hematology www.onclive.com/view/isatuxi...
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
onclive.com
This recently published study highlights the prognostic significance of high-risk cytogenetic abnormalities in multiple myeloma. Genetic alterations like t(4;14), del(17p), and +1q are linked to poorer prognosis and shorter survival #MM #hematology 👉https://bit.ly/3PzY1BT
💊 Lung Cancer FDA-approved medications in 2024 #oncsky #medsky
Oncology Brothers@oncbrothers.bsky.social · 2y ago2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA 1. #Tepotinib 2. #Osimertinib x2 3. #Alectinib 4. #Tarlatamab 5. #Zenocutuzumab 6. #Durvalumab x2 7. #Amivantamab x2 8. #Nivolumab (now SubQ) 9. #Ensartinib #lcsm #OncSky #MedSky #Cancer
This episode was great! #hemesky #lymphoma #MCL
Joshua Fein@joshuafein.bsky.social · 2y agoOUTSTANDING #ASH24 roundup of lymphoma (esp. MCL) abstracts. Is auto dead for MCL? And… not addressed, should we still consider (early) allo for young high-risk? @ash-hematology.bsky.social @berninini.bsky.social (can’t find Anthony Perissinotti or Tycel Phillips here yet? Please tag if they are!)